KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Current Investments (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Cash & Current Investments readings, the most recent being $3.7 billion for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 120.45% to $3.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 billion, a 120.45% increase, with the full-year FY2025 number at $3.6 billion, up 7.76% from a year prior.
  • Cash & Current Investments hit $3.7 billion in Q1 2026 for Teva Pharmaceutical Industries, up from $3.6 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $3.7 billion in Q1 2026 to a low of $1.7 billion in Q1 2025.
  • Median Cash & Current Investments over the past 5 years was $2.3 billion (2024), compared with a mean of $2.6 billion.
  • Biggest five-year swings in Cash & Current Investments: tumbled 43.26% in 2025 and later soared 120.45% in 2026.
  • Teva Pharmaceutical Industries' Cash & Current Investments stood at $2.8 billion in 2022, then increased by 15.17% to $3.2 billion in 2023, then rose by 2.29% to $3.3 billion in 2024, then increased by 7.76% to $3.6 billion in 2025, then grew by 5.2% to $3.7 billion in 2026.
  • The last three reported values for Cash & Current Investments were $3.7 billion (Q1 2026), $3.6 billion (Q4 2025), and $2.2 billion (Q3 2025) per Business Quant data.